Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models -

Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

Hardeep Singh Tuli (Herausgeber)

Buch | Hardcover
228 Seiten
2020 | 1st ed. 2020
Springer Verlag, Singapore
978-981-15-7585-3 (ISBN)
106,99 inkl. MwSt
This book explores potential cellular drug targets for cancer therapy. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment.
This book explores potential cellular drug targets for cancer therapy. The first couple of chapters describe conventional treatment (radiotherapy, chemotherapy, and immunotherapy) & detection (biosensors) strategies for cancer. In contrast, the subsequent chapters address the role of cyclin-dependent kinases and cell cycle regulatory proteins in the growth of cancer cells and their potential as target for cancer treatment. The book then discusses the regulation of various pro-apoptotic and anti-apoptotic proteins via chemotherapeutic drugs. In addition, it examines the molecular mechanisms that are critical for mediating autophagic cell death in cancer cells. It subsequently reviews the role of reactive oxygen (ROS) species during carcinogenesis and during chemotherapy, and the potential of anti-inflammatory routes for the development of new therapeutic modulators. Lastly, it describes therapeutic strategies that target the tumor microenvironment and various angiogenic pathways forthe treatment of cancer and to develop personalized medicine.  Given its scope, the book is valuable resource for oncologists, cancer researchers, clinicians, and pharmaceutical industry personnel.

Dr. Hardeep Singh Tuli is an Assistant Professor at the Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana Ambala. He previously served as a Lecturer at the Department of Applied Sciences, Institute of Science and Technology, Klawad, Yamunanagar (2009-2011), India. His research interests are focused on the isolation, characterization and biochemical evaluation of natural metabolites as anticancer agents. He has served as a reviewer for several international journals, and as a guest editor for the journal Frontiers in Pharmacology. He has more than 9 years of teaching and research experience in pharmacology, mammalian physiology, and natural products. He has published more than 70 papers in peer-reviewed international journals and authored a number of book chapters. In addition, Dr. Tuli is editorial board member of various national and international scientific research journals.

Chapter 1. History of oncotherapies in cancer biology.- Chapter 2. Electrochemical Sensors and Biosensors for the Detection of Cancer Biomarkers and Drugs.- Chapter 3. Cell cycle arrest: An impending therapeutic strategy to curb cancer.- Chapter 4.  Apoptotic cell death: important cellular process as chemotherapeutic target.- Chapter 5. Regulatory roles of autophagy in cancer.- Chapter 6. ROS and Oxidative Stress in Cancer: Recent Advances.- Chapter 7. Inflammatory mediators: Potential drug targets in cancer.- Chapter 8. Pharmacologic modulation of the immune response against tumours in the elderly. Chapter 9. Angiogenesis: A Therapeutic Target for Cancer.- Chapter 10. Metastasis: A major driver of cancer pathogenesis.- Chapter 11. Designing Personalized and Innovative Novel Drug Therapies For Cancer Treatment.

Erscheinungsdatum
Zusatzinfo 26 Illustrations, color; 2 Illustrations, black and white; XIII, 228 p. 28 illus., 26 illus. in color.
Verlagsort Singapore
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Studium Querschnittsbereiche Infektiologie / Immunologie
Naturwissenschaften Biologie Zellbiologie
ISBN-10 981-15-7585-1 / 9811575851
ISBN-13 978-981-15-7585-3 / 9789811575853
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Oliver Schmetzer

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
27,00